drugset
drugset / Trial / NCT00838162

A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients

NCT00838162 ↗

Phase 2 Completed 33 enrolled Tibotec Pharmaceuticals, Ireland
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the antiviral activity as measured by the change in viral load from baseline in the 14 days following initiation of treatment with 4 different dose regimens of TMC310911 co-administered with ritonavir.

Timeline

Start
2009-06
Primary completion
2009-08
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritonavir Other / unclassified 100 mg Oral
Subject TMC310911 Small molecule 75 mg Oral
Subject TMC310911 Small molecule 150 mg Oral
Subject TMC310911 Small molecule 300 mg Oral

Indications

HIV infectious disease